This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, C.-S. Articles by Gibson, N. W. Search for Related Content PubMed PubMed Citation Articles by Lee, C.-S. Articles by Gibson, N. W.

DNA Damage and Differential Cytotoxicity Produced in Human Carcinoma Cells by CC-1065 Analogues, U-73,975 and U-77,779¹

School of Pharmacy and Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033

U-73,975 (U-73) and U-77,779 (U-77), two analogues of the cyclopropylpyrroloindole antitumor antibiotic CC-1065, are promising novel chemotherapeutic agents which are known to alkylate the N3 position of adenine in a sequence-selective manner. The concentration of U-73 required to produce a 1 log cell kill in 6 human tumor cell lines varied from 20–60 pM. U-77 was more cytotoxic than U-73, with the concentrations required for a 1 log cell kill ranging from 1–20 pM. The cytotoxicity of U-73 and U-77 was found to be independent of the guanine O⁶-alkyltransferase phenotype. The sensitivity of the BE and HT-29 human colon carcinoma cells was increased when the time of drug exposure was increased from 2 to 6 h. DNA interstrand cross-links, as measured by the technique of alkaline elution, could only be detected when HT-29 or BE cells were exposed to extremely high concentrations of U-77 for 6 h. No other forms of DNA damage were detected in genomic DNA with either compound. U-77 was also found to induce DNA interstrand cross-links in naked DNA, as measured by an agarose gel method. The rate of interstrand cross-linking was extremely rapid with the "second-arm" of the cross-link being completed within 2 h. The mechanism by which these cyclopropylpyrroloindole compounds elicit their cytotoxicity, however, remains to be elucidated.

¹ Supported by a USPHS NIH grant CA 47844.

² To whom requests for reprints should be addressed, at Department of Pharmaceutical Sciences, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033.

Received 7/30/91. Accepted 10/ 4/91.

This article has been cited by other articles:

				M. C. Alley, M. G. Hollingshead, C. M. Pacula-Cox, W. R. Waud, J. A. Hartley, P. W. Howard, S. J. Gregson, D. E. Thurston, and E. A. Sausville SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 2: Efficacy Evaluations Cancer Res., September 15, 2004; 64(18): 6700 - 6706. [Abstract] [Full Text] [PDF]

				P.-r. Cao, M. M. McHugh, T. Melendy, and T. Beerman The DNA Minor Groove-alkylating Cyclopropylpyrroloindole Drugs Adozelesin and Bizelesin Induce Different DNA Damage Response Pathways in Human Colon Carcinoma HCT116 Cells Mol. Cancer Ther., July 1, 2003; 2(7): 651 - 659. [Abstract] [Full Text] [PDF]

				G. H. Schwartz, A. Patnaik, L. A. Hammond, J. Rizzo, K. Berg, D. D. Von Hoff, and E. K. Rowinsky A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies Ann. Onc., May 1, 2003; 14(5): 775 - 782. [Abstract] [Full Text] [PDF]

				H. C. Pitot, J. M. Reid, J. A. Sloan, M. M. Ames, A. A. Adjei, J. Rubin, P. G. Bagniewski, P. Atherton, D. Rayson, R. M. Goldberg, et al. A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors Clin. Cancer Res., March 1, 2002; 8(3): 712 - 717. [Abstract] [Full Text] [PDF]